PMVP PMV PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PMV PHARMACEUTICALS INC reported revenue of n/a, net income of −$18.1M and diluted EPS of −$0.34; for the fiscal year ended December 2025 revenue was n/a.
PMVP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$86.2M, net income −$77.7M (margin n/a), EPS −$1.48
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$85.4M, net income −$58.9M (margin n/a), EPS −$1.14
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$80.1M, net income −$69.0M (margin n/a), EPS −$1.44
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$77.0M, net income −$73.3M (margin n/a), EPS −$1.61
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$58.3M, net income −$57.8M (margin n/a), EPS −$1.28
PMVP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$18.1M, EPS −$0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$18.0M, EPS −$0.34
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$18.0M, EPS −$0.33
- Quarter ended Sep 30, 2025: revenue n/a, net income −$21.1M, EPS −$0.40
- Quarter ended Jun 30, 2025: revenue n/a, net income −$21.2M, EPS −$0.41
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.4M, EPS −$0.34
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$23.2M, EPS −$0.45
- Quarter ended Sep 30, 2024: revenue n/a, net income −$19.2M, EPS −$0.37
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.21M, EPS −$0.02
- Quarter ended Mar 31, 2024: revenue n/a, net income −$15.3M, EPS −$0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$15.8M, EPS −$0.30
- Quarter ended Sep 30, 2023: revenue n/a, net income −$16.6M, EPS −$0.34
- Quarter ended Jun 30, 2023: revenue n/a, net income −$17.4M, EPS −$0.38
- Quarter ended Mar 31, 2023: revenue n/a, net income −$19.1M, EPS −$0.42
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$19.3M, EPS −$0.42
- Quarter ended Sep 30, 2022: revenue n/a, net income −$18.2M, EPS −$0.40
- Quarter ended Jun 30, 2022: revenue n/a, net income −$17.3M, EPS −$0.38
- Quarter ended Mar 31, 2022: revenue n/a, net income −$18.4M, EPS −$0.41
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.4M, EPS −$0.40
- Quarter ended Sep 30, 2021: revenue n/a, net income −$15.0M, EPS −$0.33
PMVP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$73.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$51.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$55.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$63.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$46.6M, share buybacks n/a
PMVP balance sheet
- Jun 30, 2026: cash $12.5M, total assets $82.1M, total liabilities $10.6M, shareholders' equity $71.5M
- Mar 31, 2026: cash $39.1M, total assets $96.6M, total liabilities $8.60M, shareholders' equity $88.0M
- Dec 31, 2025: cash $38.0M, total assets $117M, total liabilities $11.9M, shareholders' equity $105M
- Sep 30, 2025: cash $36.3M, total assets $134M, total liabilities $12.8M, shareholders' equity $121M
- Jun 30, 2025: cash $44.1M, total assets $153M, total liabilities $12.3M, shareholders' equity $141M
- Mar 31, 2025: cash $51.3M, total assets $171M, total liabilities $10.5M, shareholders' equity $160M
- Dec 31, 2024: cash $40.9M, total assets $191M, total liabilities $15.2M, shareholders' equity $176M
- Sep 30, 2024: cash $48.8M, total assets $223M, total liabilities $25.6M, shareholders' equity $198M
Is PMVP profitable?
No. PMV PHARMACEUTICALS INC lost $75.2M over the last four quarters.
What is PMVP's EPS?
Diluted earnings per share over the last four quarters were −$1.41; −$0.34 in the latest quarter.